Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by deposition of the β-amyloid (Ab) peptide in the brain. Although many Ab-centric therapies have been attempted, they all failed and no efficacious therapy is available yet. Objectives. Main objectives of this study were to investigate the efficacy of multifunctional liposomes (Lip), designed to target the brain, to 1. promote disaggregation of brain Ab assemblies in AD mouse brain, 2. reduce brain Ab burden and 3. restore mouse memory, at a post-symptomatic stage. 4. Arrest pathology progression at a presymptomatic stage. Methods. Functionalized Lip with a peptide derived from apolipoprotein-E receptorbinding domain (mApoE) for blood-brain barrier targeting, and with phosphatidic acid (PA) for Ab binding (mApoE-PA-Lip) were administered (I.P.) for 3 weeks in post- and 4 months in pre-symptomatic APP/PS1 mice subsequently tested in the novel object recognition memory test (NORT). At the end mouse brains were collected and analyzed through histology and biochemistry for Ab deposition. Results. Administration of mApoE-PA-Lip decreased total insoluble brain Ab1-42, total plaque area and Ab oligomers. Plaque reduction was confirmed by PET imaging with [11C]-PIB. The reduction of brain Ab was associated with its increase in liver and spleen. Treatment also restored mouse impaired memory to normal at post-symptomatic ages and prevented its loss when administered at pre-symptomatic ages. Conclusions. These data suggest that bi-functionalized Lip destabilize brain Ab aggregates and promote peptide removal from the brain and its peripheral clearance. This innovative therapeutic approach can be considered as a new candidate for AD treatment.

Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., et al. (2015). A nanomedicine-based therapeutic approach restores memory and ameliorates amyloid pathology in Alzheimer's mouse models. In Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases. 12th International Conference AD/PDTM Nice, France, March 18-22, 2015: Abstracts (pp.707-707). Karger [10.1159/000381736].

A nanomedicine-based therapeutic approach restores memory and ameliorates amyloid pathology in Alzheimer's mouse models

MANCINI, SIMONA;MINNITI, STEFANIA;SANCINI, GIULIO ALFREDO;MAURI, MARIO;MASSERINI, MASSIMO ERNESTO;RE, FRANCESCA
2015

Abstract

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by deposition of the β-amyloid (Ab) peptide in the brain. Although many Ab-centric therapies have been attempted, they all failed and no efficacious therapy is available yet. Objectives. Main objectives of this study were to investigate the efficacy of multifunctional liposomes (Lip), designed to target the brain, to 1. promote disaggregation of brain Ab assemblies in AD mouse brain, 2. reduce brain Ab burden and 3. restore mouse memory, at a post-symptomatic stage. 4. Arrest pathology progression at a presymptomatic stage. Methods. Functionalized Lip with a peptide derived from apolipoprotein-E receptorbinding domain (mApoE) for blood-brain barrier targeting, and with phosphatidic acid (PA) for Ab binding (mApoE-PA-Lip) were administered (I.P.) for 3 weeks in post- and 4 months in pre-symptomatic APP/PS1 mice subsequently tested in the novel object recognition memory test (NORT). At the end mouse brains were collected and analyzed through histology and biochemistry for Ab deposition. Results. Administration of mApoE-PA-Lip decreased total insoluble brain Ab1-42, total plaque area and Ab oligomers. Plaque reduction was confirmed by PET imaging with [11C]-PIB. The reduction of brain Ab was associated with its increase in liver and spleen. Treatment also restored mouse impaired memory to normal at post-symptomatic ages and prevented its loss when administered at pre-symptomatic ages. Conclusions. These data suggest that bi-functionalized Lip destabilize brain Ab aggregates and promote peptide removal from the brain and its peripheral clearance. This innovative therapeutic approach can be considered as a new candidate for AD treatment.
abstract + poster
Abeta; Alzheimer; cognitive impairment; liposomes; nanomedicine; oligomers
English
International Conference on Alzheimer's and Parkinson's diseases. AD/PD 2015
2015
Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases. 12th International Conference AD/PDTM Nice, France, March 18-22, 2015: Abstracts
2015
15
suppl 1
707
707
http://www.karger.com/Article/Abstract/381736
reserved
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., et al. (2015). A nanomedicine-based therapeutic approach restores memory and ameliorates amyloid pathology in Alzheimer's mouse models. In Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases. 12th International Conference AD/PDTM Nice, France, March 18-22, 2015: Abstracts (pp.707-707). Karger [10.1159/000381736].
File in questo prodotto:
File Dimensione Formato  
Balducci-2015-Neurodegenerative Dis-VoR.pdf

Solo gestori archivio

Descrizione: Intervento a convegno
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 15.57 MB
Formato Adobe PDF
15.57 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/89776
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact